haematology
Blood cancers

Reports of Arzerra’s demise are greatly exaggerated

Reports that the CLL drug ofatumumab (Arzerra) is to be discontinued have been rejected by distributor Novartis. On 22 January the company from which the drug is licensed, Genmab,  announced that the monoclonal antibody treatment was to be withdrawn in all markets outside the US due to low usage. The company said ofatumumab would be ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic